Navigation Links
Spectral appoints two new board members
Date:3/10/2010

TORONTO, March 10 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced the appointment of Mr. Kevin Giese, President, CEO and Director of BioMS Medical and Mr. Laine Woollard, QC, Senior Legal Counsel of TEC Edmonton, to the Company's Board of Directors.

"Mr. Giese and Mr. Woollard will be valuable additions to the Board, bringing significant business experience," said Dr. Paul Walker, President and CEO of Spectral. "Their leadership will be important to Spectral as the Company implements its theranostics strategy in the area of sepsis."

Mr. Giese has a B.A. in economics, a law degree, and an M.B.A. He is the founding President of BioMS Medical, and has been in senior management roles and on the board of directors of a number of private and publicly listed companies. He is a past advisory board member of the Institute of Corporate Directors (Canada) and is currently a member of the Board of Directors of BioAlberta. In 2005, he received the BioAlberta Award for Entrepreneurship.

Mr. Woollard has degrees in Pharmacy and Pharmaceu
'/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
2. Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
3. Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
4. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
5. Spectral appoints new board member
6. Spectral announces second quarter 2009 results
7. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
8. Spectral announces first quarter 2009 results
9. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
10. Spectral announces 2008 financial results
11. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... York, August 15 XTL,Biopharmaceuticals Ltd. (NASDAQ: ... engaged in the acquisition, development and,commercialization of therapeutics ... pain and hepatitis C, today announced its,financial results ... At June 30, 2007, the Company had ...
... Chilcott,Limited (Nasdaq: WCRX ) announced today that it ... Inc. ("Barr") advising the,Company of the filing of an ... FEMCON FE. FEMCON FE, which was introduced by ... chewable oral contraceptive and is protected by U.S. Patent,No. ...
... Aug. 15 Thoratec,Corporation (Nasdaq: THOR ), a ... that its PMA (PreMarket Application),seeking approval of its HeartMate ... panel later this year. The company said that ... date for the review by a Circulatory Systems Device ...
Cached Biology Technology:XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 2XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 3XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 4XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 5XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 6XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 7XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 8XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 9XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 10XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 11XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 12XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 13XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007 14Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel 2
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... (June 17, 2008) For those patients who receive ... treat their B12 deficiency, a new oral option may ... of Health, vitamin B12 deficiency can lead to a ... reduced cognitive functioning. Vitamin B12 deficiency is a significant ...
... . Montreal, 13 June 2008 ... University and the University of British Columbia (UBC) determined ... increase in serious adverse events, but are associated with ... Several drugs containing compounds derived from the cannabis plant, ...
... Assistant Investigator, has been named a Pew Scholar in ... carries an award of $240,000 over four years. ... selected on the basis of performance during education and ... science relevant to human health. The Pew Charitable Trusts ...
Cached Biology News:New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Medicines derived from cannabis: a review of adverse events 2Julia Zeitlinger named Pew Scholar 2
... and negatively supercoiled DNA in presence of EDTA ... effects of supercoiling on transcription in vitro ... Determining the degree of supercoiling of naturally occurring ... in length by only one base-pair , ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: